Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FOLEX vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved: Treatment of neoplastic diseases (e.g., acute lymphoblastic leukemia, breast cancer, head and neck cancer, non-Hodgkin lymphoma, osteosarcoma),FDA-approved: Treatment of severe psoriasis (adult, recalcitrant, disabling),FDA-approved: Treatment of active rheumatoid arthritis (adult, severe, active) and polyarticular juvenile idiopathic arthritis,Off-label: Management of ectopic pregnancy,Off-label: Treatment of Crohn's disease,Off-label: Management of uveitis
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal half-life: 3-10 hours (mean ~5 hours) for low-dose regimens; higher doses or renal impairment may prolong half-life up to 24 hours.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Methotrexate undergoes hepatic metabolism to polyglutamate metabolites which are retained in cells. It is partially metabolized by aldehyde oxidase and xanthine oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily renal excretion of unchanged drug: ~80-90% within 24 hours. Biliary/fecal excretion accounts for <10%.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 50% bound to serum proteins, primarily albumin.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Vd: 0.4-0.8 L/kg (total body water), indicating extensive tissue distribution; higher in pleural effusions or ascites.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral bioavailability: dose-dependent, variable (20-80%, higher with low doses); IM: complete but slower absorption; IV: 100%.
Intravenous administration yields 100% bioavailability.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use or reduce dose by 75%.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
For acute lymphoblastic leukemia: 12.5 mg/m2 orally once weekly; for juvenile idiopathic arthritis: 10-15 mg/m2 orally or subcutaneously once weekly. Maximum single dose: 20 mg.
Safety and effectiveness in pediatric patients have not been established.
Start at lowest end of dosing range (e.g., 5-7.5 mg orally weekly for rheumatoid arthritis) due to increased risk of toxicity from reduced renal function and folate stores.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
FOLEX (methotrexate) may cause severe toxicity including death, especially with high doses. Severe reactions include myelosuppression, hepatotoxicity, pulmonary fibrosis, renal failure, and gastrointestinal ulceration. Must be used only by physicians experienced in antimetabolite therapy. Patients should be closely monitored for bone marrow, liver, and renal toxicity.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Hepatotoxicity: Risk of acute and chronic liver injury, fibrosis, and cirrhosis, especially with prolonged use or pre-existing liver disease,Myelosuppression: Risk of severe pancytopenia, especially in renal impairment or with concurrent NSAIDs,Pulmonary toxicity: Acute or chronic interstitial pneumonitis, fibrosis,Renal toxicity: Acute renal failure due to precipitation of methotrexate in renal tubules, especially with high doses,Gastrointestinal toxicity: Ulceration, perforation, hemorrhage,Dermatologic reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Concurrent NSAIDs increase methotrexate toxicity
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Hypersensitivity to methotrexate or any component,Breastfeeding,Severe renal impairment (creatinine clearance <10 m L/min),Severe hepatic impairment (e.g., cirrhosis, active hepatitis),Pre-existing severe bone marrow depression (e.g., pancytopenia),Pregnancy (teratogenic and embryotoxic)
None known.
Avoid alcohol completely; may increase hepatotoxicity. No specific food restrictions, but maintain adequate hydration. Avoid folic acid-rich foods (e.g., fortified cereals, legumes) if combining with leucovorin rescue in high-dose therapy due to potential interference. Take folic acid supplements at a different time than methotrexate if prescribed.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
FDA Pregnancy Category X. First trimester: High risk of miscarriage, neural tube defects, craniofacial anomalies, and limb defects. Second and third trimesters: Fetal growth restriction, skeletal abnormalities, functional deficits. Avoid use during pregnancy.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Contraindicated during breastfeeding. Methotrexate (active component) is excreted in breast milk with an M/P ratio of approximately 0.08; risk of infant accumulation due to long half-life. Do not breastfeed during therapy or for at least 1 week after last dose.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
Pregnancy is a contraindication; no dose adjustments are recommended. If used inadvertently, immediate discontinuation and high-dose folic acid rescue. Pharmacokinetic changes in pregnancy (increased Vd and clearance) may require dose reduction if used for non-pregnant patients, but absolute contraindication overrides.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
Folex (methotrexate) is a folate analog antimetabolite used in oncology and autoimmune diseases. Administer leucovorin rescue 24 hours after high-dose methotrexate to prevent severe toxicity. Monitor renal function and methotrexate levels closely. Avoid NSAIDs as they reduce renal clearance and increase toxicity. Hepatotoxicity and pulmonary fibrosis are serious adverse effects. Intrathecal administration requires preservative-free formulation.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take folic acid supplements as prescribed to reduce side effects unless on high-dose therapy with leucovorin rescue.,Avoid alcohol completely during treatment due to increased risk of liver damage.,Report any signs of infection, unusual bleeding, or shortness of breath immediately.,Drink plenty of fluids to help flush the drug from your kidneys unless otherwise instructed.,Do not take any over-the-counter medications, especially NSAIDs (like ibuprofen), without consulting your doctor.,Use effective contraception during and for at least 3 months after treatment for both men and women.,Follow your dosing schedule exactly; missed doses can reduce effectiveness or increase toxicity.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FOLEX vs COLUMVI, answered by our medical review team.
FOLEX is a Antineoplastic Agent that works by Methotrexate, the active ingredient in FOLEX, is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with thymidylate and purine synthesis, leading to inhibition of DNA replication and cell proliferation.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FOLEX and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FOLEX is: 30 mg/m2 intravenously once weekly for 2 weeks followed by a 1-week rest period, or 5-10 mg/m2 intramuscularly or intravenously every 3-4 weeks. For rheumatoid arthritis, 7.5-15 mg orally once weekly.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FOLEX and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FOLEX is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of miscarriage, neural tube defects, craniofacial anomalies, and limb defects. Second and third trimesters: Fetal growth restri. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.